Marlio Charles Mosseri bought $270k of NVCT
owner at Nuvectis Pharma, Inc.. 33,442 shares at an average of $8.06, traded Jun 17, 2025, filed Jun 20, 2025.
Score components
- +12Role10% owner
- +13Trade size$270k at market
- 0Relative to holdingsHoldings up 1.1%
- +4Price context26% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.1%, 3m -22.9%, 6m -4.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-060965, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 17, 2025 | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +5,399 | $8.11 | $44k | 2,948,160 | Jun 20, 2025 |
| Jun 18, 2025 | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +28,043 | $8.05 | $226k | 2,976,203 | Jun 20, 2025 |
Related signals
Other insiders at Nuvectis Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 59Moderate | Nuvectis Pharma, Inc. | Ron Bentsur Chairman & CEO | $250k 12,500 shares | +0% | |
| 47Moderate | Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $916k 50,000 shares | +2% | |
| 48Moderate | Nuvectis Pharma, Inc. | Ron Bentsur Chairman & CEO | $29k 5,000 shares | +0% | |
| 49Moderate | Nuvectis Pharma, Inc. | Matthew L. Kaplan director | $64k 11,000 shares | +10% | |
| 49Moderate | Nuvectis Pharma, Inc. | Juan Sanchez director | $75k 13,000 shares | +20% | |
| 57Moderate | Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $957k 154,770 shares | +5% | |
| 17Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $45k 5,603 shares | +0% | |
| 22Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $172k 21,167 shares | +1% | |
| 24Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $247k 27,662 shares | +1% | |
| 19Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $236k 27,411 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.